Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1998-12-28
|
pubmed:abstractText |
The in-vitro activity of a combination of ranitidine bismuth citrate (RBC) and metronidazole against metronidazole-resistant Helicobacter pylori strains (MIC > or = 8 mg/L) was evaluated by agar dilution chequerboard and killing curve methods. Twenty-five metronidazole-resistant strains were used in the chequerboard method, using Mueller-Hinton agar plus 7% lysed horse blood, an inoculum of 10(6) cfu/spot and incubation in a 10% CO2 atmosphere at 37 degrees C for 3-5 days. Synergy was defined as a fractional inhibitory concentration (FIC) index of < or = 0.5, partial synergy as 0.5 < FIC < or = 1, indifference as 1 < FIC < or = 4 and antagonism as FIC > 4. For nine strains, killing curves were constructed for metronidazole and RBC individually and in combination at 1 x MIC. The number of viable colonies was counted at time 0 and after 2, 4, 6, 8 and 24 h; the combination was defined as synergic if it produced a decrease of > or = 2 log10 cfu/mL compared with the most active single agent. Metronidazole MICs ranged from 8 to 128 mg/L and RBC MICs from 0.125 to 4 mg/L. The minimum FIC ranged from 0.28 to 1 and the maximum FIC from 1 to 1.25. When RBC and metronidazole were combined, all the metronidazole-resistant H. pylori strains revealed partial (68%) or total (32%) synergy. Five out of the nine strains also exhibited synergy at 4, 6 or 8 h incubation when tested by the killing curve method although three other strains exhibited no synergy. In the last strain, a 2log10 decrease in the initial number was observed with RBC alone or combined with metronidazole.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Bismuth,
http://linkedlifedata.com/resource/pubmed/chemical/Metronidazole,
http://linkedlifedata.com/resource/pubmed/chemical/Ranitidine,
http://linkedlifedata.com/resource/pubmed/chemical/ranitidine bismuth citrate
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0305-7453
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
309-14
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9786470-Anti-Bacterial Agents,
pubmed-meshheading:9786470-Bismuth,
pubmed-meshheading:9786470-Drug Resistance, Microbial,
pubmed-meshheading:9786470-Drug Synergism,
pubmed-meshheading:9786470-Helicobacter pylori,
pubmed-meshheading:9786470-Humans,
pubmed-meshheading:9786470-Metronidazole,
pubmed-meshheading:9786470-Microbial Sensitivity Tests,
pubmed-meshheading:9786470-Ranitidine
|
pubmed:year |
1998
|
pubmed:articleTitle |
Study of the combination of ranitidine bismuth citrate and metronidazole against metronidazole-resistant Helicobacter pylori clinical isolates.
|
pubmed:affiliation |
Department of Microbiology, Hospital Universitario de la Princesa, Madrid, Spain. mlbrea@microb.net
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|